Emris Pharma Israeli Company
EMRIS Pharma is developing a novel small molecule topically administrated for the prevention of skin toxicities induced by EGFR inhibitors (EGFRi). This innovative therapy intends to improve cancer patients’ quality of life and compliance with cancer therapy.
Health Tech & Life Sciences
Health Care
Medical
Pharmaceutical
Wellness
Alternatives
No alternatives listed yet.
AI-Generated Alternatives
Powered by AI May contain mistakes
AI is thinking and generating alternatives...
{
$el.querySelectorAll('a').forEach(link => {
link.target = '_blank';
link.rel = 'noopener noreferrer';
});
})"
class="ai-alternatives-content prose prose-sm dark:prose-invert prose-headings:text-gray-900 dark:prose-headings:text-gray-100 prose-p:text-gray-700 dark:prose-p:text-gray-300 prose-strong:text-gray-900 dark:prose-strong:text-gray-100 max-w-none [&>h2]:mb-4 [&>h2]:mt-8 [&>h3]:mb-3 [&>h3]:mt-6 [&>p]:mb-4 [&>ul>li]:my-2 [&>ul]:space-y-3"
>
Suggest an Alternative
Parent Companies/Investors
Office Locations
Nazareth, Israel
References
[1]
finder.startupnationcentral.org
- https://finder.startupnationcentral.org/company_page/emris-pharma
[2]
crunchbase.com
- https://www.crunchbase.com/organization/emris-pharma
External links are provided for reference and verification purposes.